Management of Migrainous Vertigo Patients: Review Article

Authors

  • Soha Abd-Elraouf Mekki
  • Mohammad Ramadan Hassaan
  • Tamer Sabry Elserafy
  • Lobna Ibrahim Mohamed Assaf
  • Nahla Gad

Keywords:

Vestibular migraine, vertigo, migraine-associated vertigo, vestibular rehabilitation, prophylaxis, calcium channel blocker, beta-blocker, triptans

Abstract

Vestibular migraine (VM) is one of the most common causes of recurrent vertigo, affecting approximately 1% of the general population and up to 10% of patients seen in dizziness clinics. It is characterized by episodic vertigo associated with migraine features such as headache, photophobia, phonophobia, or visual aura. The exact pathophysiology remains unclear, but it likely involves central mechanisms linking vestibular pathways and migraine-related neuronal excitability, particularly in the brainstem and cerebellum. Diagnosis is primarily clinical, based on the Bárány Society and International Headache Society criteria, which require at least five episodes of vestibular symptoms lasting 5 minutes to 72 hours, with a current or past history of migraine and migraine features during at least half of the episodes. Vestibular migraine is more common in women and typically presents in middle adulthood, although onset may occur at any age. The management of vestibular migraine involves a multidisciplinary approach targeting lifestyle modification, trigger identification, acute attack management, and long-term prophylaxis...

Downloads

Download data is not yet available.

References

[1] Lovato A, Disco C, Frosolini A, Monzani D, Perini F. (2023). Monoclonal antibodies targeting CGRP: a novel treatment in vestibular migraine. Medicina (Kaunas); Aug 28;59(9):1560.

[2] Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. (2020). Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020 Mar 31;94(13): e1365–77.

[3] Haghdoost F, Togha M. (2022). Migraine management: non-pharmacological points for patients and health care professionals. Open Med.; Nov 23;17(1): 1869–82.

[4] Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont Benjamin L. (2022). Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. Cephalalgia 2022 Dec;42(14):1543–64.

[5] Dieterich M, Staab JP, Brandt T. (2016). Functional (psychogenic) dizziness. Handb Clin Neurol; 139:447–68.

[6] Ha H, Gonzalez A. (2019). Migraine headache prophylaxis. Am Fam Physician 2019 Jan 1; 99(1):17–24.

[7] Burch R. (2021). Preventive migraine treatment. Continuum 2021 Jun 1;27(3):613–32.

[8] Hac N.E.F., Gold D.R. (2022). Neuro-visual and vestibular manifestations of concussion and mild TBI. Curr Neurol Neurosci Rep. Mar;22(3):219–228. doi: 10.1007/s11910-022-01184-9. [DOI] [PubMed] [Google Scholar]

[9] Salviz M., Yuce T., Acar H., Karatas A., Acikalin R.M. (2016). Propranolol and venlafaxine for vestibular migraine prophylaxis: A randomized controlled trial. Laryngoscope; 126:169–174.

[10] Van Ombergen A., Van Rompaey V., Van de Heyning P., Wuyts F. (2015). Vestibular migraine in an otolaryngology clinic: prevalence, associated symptoms, and prophylactic medication effectiveness. Otology & Neurotology;36(1):133–138.

[11] Gode S, et al. (2010). Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache ;50(1):77–84.

[12] Salmito MC, et al. (2017). Prophylactic treatment of vestibular migraine. Braz J Otorhinolaryngol. ;83(4):404-10.

[13] Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G, et al. (2018). Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain; Oct 1;19(1):92.

[14] Lionetto L, Cipolla F, Guglielmetti M, Martelletti P. (2019). Fremanezumab for the prevention of chronic and episodic migraine. Drugs Today Apr;55(4): 265–76.

[15] Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. (2021). Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 2021 Jan 2;397(10268): 51–60.

[16] Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. (2021). ADVANCE study group. Atogepant for the preventive treatment of migraine. N Engl J Med 2021 Aug 19;385(8):695–706.

[17] Shaterian N, Shaterian N, Ghanaatpisheh A, Abbasi F, Daniali S, Jahromi MJ, et al. (2022) Botox (OnabotulinumtoxinA) for treatment of migraine symptoms: a systematic review. Pain Res Manag, Mar 31; 2022:3284446.

[18] Webster KE, Dor A, Galbraith K, Haj Kassem L, Harrington-Benton NA, Judd O, et al. (2023). Pharmacological interventions for acute attacks of vestibular migraine. Cochrane Database Syst Rev Apr 12;4(4):CD015322.

[19] Beh SC (2019) External trigeminal nerve stimulation: Potential rescue treatment for acute vestibular migraine. J Neurol Sci. Oct 25;408

[20] Beh S.C., Masrour S., Smith S.V. and Friedman D.I. (2019). The spectrum of vestibular migraine: clinical features, triggers, and examination findings, Headache 59, 727–740.

[21] Herdman SJ, Hall CD, Schubert MC, Das VE, Tusa RJ (2007). Recovery of dynamic visual activity in bilateral vestibular hypofunction. Arch Otolaryngol Head Neck Surg.; 133:383---9.

[22] Lacour M (2013). Betahistine treatment in managing vertigo and improving vestibular compensation: clarification. J vestibul res equilib orientat.;23:139–151.

[23] A.H. Alghadir, S. Anwer (2020) Effects of vestibular rehabilitation in the management of a vestibular migraine: a review (2022) Central vestibular dysfunction: don’t forget vestibular rehabilitation, Expert Review of (Open in a new window)PubMed(Open in a new window)Google Scholar; 40:107–121.

[24] Hall CD, Herdman SJ, Whitney SL, et al. (2016). Vestibular rehabilitation for peripheral vestibular hypofunction: an evidence-based clinical practice guideline: from the American physical therapy association neurology section. J Neurol Phys Ther.;40:124–155.

[25] Furman JM, Marcus DA, Balaban CD (2013) Vestibular migraine: clinical aspects and pathophysiology. Lancet Neurol 12(7):706–715

[26] Jafarzadeh S, Pourbakht A, Bahrami E, et al. (2018) Effect of early vestibular rehabilitation on vertigo and unsteadiness in patients with acute and sub-acute head trauma. Iran J Otorhinolaryngol.;30:85–90.

[27] Angelaki, D., & Cullen, K. (2008): Vestibular system: the many facets of a multimodal sense. Annual Review of Neuroscience; (31): 125-150. aspects and pathophysiology. Lancet Neurol. 2013; 12:706–715.

[28] MacDougall, H., & Curthoys, I. (2012): Plasticity during vestibular compensation: the role of saccades. Frontiers in neurology; (3): 21.

[29] Pavlou M, Quinn C, Murray K, Spyridakou C, Faldon M, Bronstein AM (2011). The effect of repeated visual motion stimuli on visual dependence and postural control in normal subjects. Gait & Posture; 33:113-118.

[30] Chen, S., & Wilkinson, E. (2019): Mechanism of Compensation After Unilateral Loss. Diagnosis and Treatment of Vestibular Disorders; 17-24.

[31] Sahin E, Dinc ME, Ozker BY, Cöpürgensli C, Konaklıoglu M, Ozcelik T (2017). The value of vestibular rehabilitation in patients with bilateral vestibular dysfunction. J Int Adv Otol.;13: 385---9.

[32] Vitkovic J, Winoto A, Rance G, Dowell R, Paine M (2013). Vestibular rehabilitation outcomes in patients with and without vestibular migraine. J Neurol.; 260:3039---48.

[33] Lauritsen CG, Marmura MJ (2017). Current treatment options: vestibular migraine. Curr Treat Options Neurol.;19: 38.

[34] Park MK, Lee DY and Kim YH (2019). Risk fac tors for positional vertigo and the impact of vertigo on daily life: the Korean National Health and Nutrition Examination Survey. J Audiol Otol; 23: 8–14.

[35] Karapolat H, Eyigor S, Kirazlı Y (2009). Reliability, validity, and sensitivity to change of Turkish dizziness handicap inventory (DHI) in patients with unilateral peripheral vestibular disease. Int Adv Otol; 5:237 45

[36] Goto F, Yamamoto N, Shindo A, Minami S, Tokumaru Y, Fujii M (2014). The different effects of group in-hospital rehabilitation on younger and older patients with intractable dizziness [in Japanese]. Iryo 68:175–81. [Google Scholar]

[37] McDonnell MN, Hillier SL (2015). Vestibular rehabilitation for unilateral peripheral vestibular dysfunction. Cochrane Database Syst Rev.;13(1):CD005397.

[38] Jacobson GP, Newman CW (1990). The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg.; 116:424---7.

[39] Wrisley D.M., Whitney S.L., Furman J.M (2002). Vestibular rehabilitation outcomes in patients with a history of migraine. Otol Neurotol, 23, pp. 483-487..

Downloads

Published

2024-10-10

How to Cite

1.
Abd-Elraouf Mekki S, Ramadan Hassaan M, Elserafy TS, Mohamed Assaf LI, Gad N. Management of Migrainous Vertigo Patients: Review Article. J Neonatal Surg [Internet]. 2024 Oct. 10 [cited 2026 Feb. 3];13(1):1869-77. Available from: https://jneonatalsurg.com/index.php/jns/article/view/9698

Issue

Vol. 13 (2024): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.